Aclaris Therapeutics Earns 'Moderate Buy' Rating from Analysts
Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biotech company, has received a consensus 'Moderate Buy' recommendation from analysts, with an average 12-month price target of $9.80 per share. This rating reflects potential in the company's pipeline for dermatological conditions, despite varying analyst recommendations from 'sell' to 'strong buy'. The stock opened at $3.75 on Wednesday, April 8, 2026, with a 52-week range of $1.05 to $4.89.
How this was made
The 30-second read
Why it matters
The positive analyst sentiment could lead to increased investor interest and stock appreciation, but clinical and regulatory risks remain.
Market read
The news is relevant primarily to biotech investors and those interested in dermatology therapeutics, with potential sector-wide implications.
What to watch
Potential delays in clinical trials or regulatory approvals could negatively impact stock performance, which may not be fully reflected in current analyst ratings.
Background
Aclaris Therapeutics is a biotech firm focusing on dermatological treatments, currently in clinical development stages.
Ticker impact
The news pertains directly to Aclaris Therapeutics, a biotech company with a 'Moderate Buy' analyst rating.
Moderate upward price movement expected over the next 12 months, with potential for short-term gains.
The analyst consensus and price target indicate positive sentiment; however, the variability in analyst ratings and the company's clinical-stage status introduce uncertainty.
Market effects
Potential positive impact on biotech and dermatology sectors due to increased investor interest.
Limited regional impact; primarily relevant to US markets where the company is listed.
Moderate, as biotech stocks can influence global healthcare investment trends.
Counterpoint
Some analysts may view the 'Moderate Buy' rating as overly optimistic given the company's clinical-stage status and potential pipeline risks.
Key entities
- CompanyAclaris Therapeutics
A clinical-stage biotech company specializing in dermatology.
